ALPS Advised Funds > ALPS ETF Trust
ALPS Medical Breakthroughs ETF
$103.42M
Avg Monthly Net Assets
$103.38M
Total Assets
$46K
Total Liabilities
$103.33M
Net Assets
ALPS Medical Breakthroughs ETF is an Exchange-Traded Fund in ALPS ETF Trust
from ALPS Advised Funds,
based in Colorado,
United States of America.
The fund has one share class
and monthly net assets of $103.42M.
On July 30th, 2024 it reported 96 holdings, the largest
being Vaxcyte Inc (5.2%), Cerevel Therapeutics Holdings Inc (5.0%) and Viking Therapeutics Inc (4.5%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Exchange | Ticker | Monthly Returns (2 years) |
|---|---|---|---|---|
| ALPS Medical Breakthroughs ETF | C000150206 | ARCX | SBIO |
Holdings
From latest NPORT-P, filed July 30th, 2024 for period ending May 31st, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (4d Molecular Therapeutics Inc) | Long | Equity-common | US | $838K | 35K | 0.81 |
| 89bio, Inc. (89bio Inc) | Long | Equity-common | US | $519K | 66K | 0.50 |
| ACADIA Pharmaceuticals, Inc. (Acadia Pharmaceuticals Inc) | Long | Equity-common | US | $2M | 116K | 1.69 |
| ACELYRIN, Inc. (Acelyrin Inc) | Long | Equity-common | US | $279K | 68K | 0.27 |
| Aerovate Therapeutics, Inc. (Aerovate Therapeutics Inc) | Long | Equity-common | US | $340K | 19K | 0.33 |
| Agios Pharmaceuticals, Inc. (Agios Pharmaceuticals Inc) | Long | Equity-common | US | $1M | 39K | 1.39 |
| Akero Therapeutics, Inc. (Akero Therapeutics Inc) | Long | Equity-common | US | $744K | 40K | 0.72 |
| Alector, Inc. (Alector Inc) | Long | Equity-common | US | $331K | 67K | 0.32 |
| Alkermes PLC | Long | Equity-common | IE | $3M | 118K | 2.67 |
| Allogene Therapeutics, Inc. (Allogene Therapeutics Inc) | Long | Equity-common | US | $293K | 117K | 0.28 |
| Amylyx Pharmaceuticals, Inc. (Amylyx Pharmaceuticals Inc) | Long | Equity-common | US | $79K | 46K | 0.08 |
| AnaptysBio, Inc. (Anaptysbio Inc) | Long | Equity-common | US | $448K | 19K | 0.43 |
| Anavex Life Sciences Corp. | Long | Equity-common | US | $232K | 57K | 0.22 |
| Arcellx, Inc. (Arcellx Inc) | Long | Equity-common | US | $2M | 37K | 1.87 |
| Arcturus Therapeutics Holdings, Inc. (Arcturus Therapeutics Holdings Inc) | Long | Equity-common | US | $729K | 19K | 0.71 |
| Arcus Biosciences, Inc. (Arcus Biosciences Inc) | Long | Equity-common | US | $963K | 64K | 0.93 |
| ARS Pharmaceuticals, Inc. (Ars Pharmaceuticals Inc) | Long | Equity-common | US | $599K | 67K | 0.58 |
| Arvinas, Inc. (Arvinas Inc) | Long | Equity-common | US | $2M | 48K | 1.53 |
| AstraZeneca PLC | Derivative-equity | US | $0.04 | – | 0.00 | |
| Atea Pharmaceuticals, Inc. (Atea Pharmaceuticals Inc) | Long | Equity-common | US | $215K | 59K | 0.21 |
| Aura Biosciences, Inc. (Aura Biosciences Inc) | Long | Equity-common | US | $252K | 34K | 0.24 |
| Aurinia Pharmaceuticals, Inc. (Aurinia Pharmaceuticals Inc) | Long | Equity-common | CA | $551K | 102K | 0.53 |
| Avidity Biosciences, Inc. (Avidity Biosciences Inc) | Long | Equity-common | US | $2M | 56K | 1.46 |
| Axsome Therapeutics, Inc. (Axsome Therapeutics Inc) | Long | Equity-common | US | $2M | 33K | 2.37 |
| Azn Ln - Cvr | Derivative-equity | GB | $0.04 | – | 0.00 | |
| BioCryst Pharmaceuticals, Inc. (Biocryst Pharmaceuticals Inc) | Long | Equity-common | US | $935K | 145K | 0.91 |
| Biomea Fusion, Inc. (Biomea Fusion Inc) | Long | Equity-common | US | $262K | 25K | 0.25 |
| Catalyst Pharmaceuticals, Inc. (Catalyst Pharmaceuticals Inc) | Long | Equity-common | US | $1M | 83K | 1.30 |
| Celldex Therapeutics, Inc. (Celldex Therapeutics Inc) | Long | Equity-common | US | $2M | 45K | 1.46 |
| Cerevel Therapeutics Holdings, Inc. (Cerevel Therapeutics Holdings Inc) | Long | Equity-common | KY | $5M | 128K | 5.04 |
| Chinook Therapeutics, Inc. (Chinook Therapeutics Inc) | Derivative-equity | US | $0.02 | – | 0.00 | |
| Compass Pathways PLC | Long | Equity-common | GB | $330K | 45K | 0.32 |
| Corcept Therapeutics, Inc. (Corcept Therapeutics Inc) | Long | Equity-common | US | $2M | 73K | 2.13 |
| Crinetics Pharmaceuticals, Inc. (Crinetics Pharmaceuticals Inc) | Long | Equity-common | US | $2M | 55K | 2.36 |
| Day One Biopharmaceuticals, Inc. (Day One Biopharmaceuticals Inc) | Long | Equity-common | US | $814K | 61K | 0.79 |
| Deciphera Pharmaceuticals, Inc. (Deciphera Pharmaceuticals Inc) | Long | Equity-common | US | $1M | 57K | 1.40 |
| Denali Therapeutics, Inc. (Denali Therapeutics Inc) | Long | Equity-common | US | $2M | 98K | 1.76 |
| Disc Medicine, Inc. (Disc Medicine Inc) | Long | Equity-common | US | $577K | 17K | 0.56 |
| Edgewise Therapeutics, Inc. (Edgewise Therapeutics Inc) | Long | Equity-common | US | $1M | 65K | 1.09 |
| Enanta Pharmaceuticals, Inc. (Enanta Pharmaceuticals Inc) | Long | Equity-common | US | $185K | 15K | 0.18 |
| Fulcrum Therapeutics, Inc. (Fulcrum Therapeutics Inc) | Long | Equity-common | US | $342K | 44K | 0.33 |
| Galapagos NV | Long | Equity-common | BE | $1M | 47K | 1.25 |
| Geron Corp. | Long | Equity-common | US | $1M | 384K | 1.32 |
| Ideaya Biosciences, Inc. (Ideaya Biosciences Inc) | Long | Equity-common | US | $2M | 52K | 1.83 |
| Immunocore Holdings PLC | Long | Equity-common | GB | $2M | 35K | 1.66 |
| Inozyme Pharma, Inc. (Inozyme Pharma Inc) | Long | Equity-common | US | $207K | 43K | 0.20 |
| Intellia Therapeutics, Inc. (Intellia Therapeutics Inc) | Long | Equity-common | US | $1M | 68K | 1.40 |
| Ironwood Pharmaceuticals, Inc. (Ironwood Pharmaceuticals Inc) | Long | Equity-common | US | $693K | 110K | 0.67 |
| iTeos Therapeutics, Inc. (Iteos Therapeutics Inc) | Long | Equity-common | US | $421K | 25K | 0.41 |
| Keros Therapeutics, Inc. (Keros Therapeutics Inc) | Long | Equity-common | US | $1M | 25K | 1.15 |
| Kiniksa Pharmaceuticals, Ltd. (Kiniksa Pharmaceuticals Ltd) | Long | Equity-common | BM | $535K | 28K | 0.52 |
| Kura Oncology, Inc. (Kura Oncology Inc) | Long | Equity-common | US | $1M | 54K | 1.07 |
| Liquidia Corp. | Long | Equity-common | US | $686K | 53K | 0.66 |
| MacroGenics, Inc. (Macrogenics Inc) | Long | Equity-common | US | $178K | 44K | 0.17 |
| MannKind Corp. | Long | Equity-common | US | $887K | 190K | 0.86 |
| Merus NV | Long | Equity-common | NL | $2M | 41K | 2.10 |
| MiMedx Group, Inc. (Mimedx Group Inc) | Long | Equity-common | US | $738K | 103K | 0.71 |
| Mineralys Therapeutics, Inc. (Mineralys Therapeutics Inc) | Long | Equity-common | US | $366K | 29K | 0.35 |
| Mirum Pharmaceuticals, Inc. (Mirum Pharmaceuticals Inc) | Long | Equity-common | US | $787K | 33K | 0.76 |
| MoonLake Immunotherapeutics | Long | Equity-common | KY | $2M | 42K | 1.66 |
| Morphic Holding, Inc. (Morphic Holding Inc) | Long | Equity-common | US | $1M | 35K | 1.03 |
| Neumora Therapeutics, Inc. (Neumora Therapeutics Inc) | Long | Equity-common | US | $1M | 107K | 1.03 |
| Olema Pharmaceuticals, Inc. (Olema Pharmaceuticals Inc) | Long | Equity-common | US | $375K | 39K | 0.36 |
| OmniAb Operations, Inc. (Omniab Operations Inc) | Derivative-equity | US | $0 | – | – | |
| OmniAb Operations, Inc. (Omniab Operations Inc) | Derivative-equity | US | $0 | – | – | |
| OPKO Health, Inc. (Opko Health Inc) | Long | Equity-common | US | $671K | 490K | 0.65 |
| Pliant Therapeutics, Inc. (Pliant Therapeutics Inc) | Long | Equity-common | US | $514K | 42K | 0.50 |
| Protagonist Therapeutics, Inc. (Protagonist Therapeutics Inc) | Long | Equity-common | US | $1M | 41K | 1.11 |
| Prothena Corp. PLC (Prothena Corp Plc) | Long | Equity-common | IE | $785K | 38K | 0.76 |
| Radius Health CVR | Derivative-equity | US | $0.03 | – | 0.00 | |
| RAPT Therapeutics, Inc. (Rapt Therapeutics Inc) | Long | Equity-common | US | $97K | 24K | 0.09 |
| Reneo Pharmaceuticals, Inc. (Reneo Pharmaceuticals Inc) | Long | Equity-common | US | $37K | 23K | 0.04 |
| Replimune Group, Inc. (Replimune Group Inc) | Long | Equity-common | US | $225K | 43K | 0.22 |
| REVOLUTION Medicines, Inc. (Revolution Medicines Inc) | Long | Equity-common | US | $4M | 116K | 4.30 |
| Rhythm Pharmaceuticals, Inc. (Rhythm Pharmaceuticals Inc) | Long | Equity-common | US | $2M | 42K | 1.46 |
| Savara, Inc. (Savara Inc) | Long | Equity-common | US | $389K | 95K | 0.38 |
| Soleno Therapeutics, Inc. (Soleno Therapeutics Inc) | Long | Equity-common | US | $903K | 21K | 0.87 |
| SpringWorks Therapeutics, Inc. (Springworks Therapeutics Inc) | Long | Equity-common | US | $2M | 52K | 2.09 |
| State Street Institutional Treasury Plus Money Market Fund | Long | Short-term investment vehicle | US | $229K | 229K | 0.22 |
| State Street Navigator Securities Lending Government Money Market Portfolio | Long | Short-term investment vehicle | US | $0 | 0 | – |
| Summit Therapeutics, Inc. (Summit Therapeutics Inc) | Long | Equity-common | US | $4M | 493K | 4.14 |
| Syndax Pharmaceuticals, Inc. (Syndax Pharmaceuticals Inc) | Long | Equity-common | US | $1M | 60K | 1.11 |
| Tarsus Pharmaceuticals, Inc. (Tarsus Pharmaceuticals Inc) | Long | Equity-common | US | $868K | 26K | 0.84 |
| Travere Therapeutics, Inc. (Travere Therapeutics Inc) | Long | Equity-common | US | $397K | 53K | 0.38 |
| Vanda Pharmaceuticals, Inc. (Vanda Pharmaceuticals Inc) | Long | Equity-common | US | $205K | 40K | 0.20 |
| Vaxcyte, Inc. (Vaxcyte Inc) | Long | Equity-common | US | $5M | 76K | 5.18 |
| Vera Therapeutics, Inc. (Vera Therapeutics Inc) | Long | Equity-common | US | $1M | 39K | 1.42 |
| Vericel Corp. | Long | Equity-common | US | $2M | 34K | 1.57 |
| Verona Pharma PLC | Long | Equity-common | GB | $685K | 57K | 0.66 |
| Viking Therapeutics, Inc. (Viking Therapeutics Inc) | Long | Equity-common | US | $5M | 74K | 4.45 |
| Vir Biotechnology, Inc. (Vir Biotechnology Inc) | Long | Equity-common | US | $974K | 95K | 0.94 |
| Viridian Therapeutics, Inc. (Viridian Therapeutics Inc) | Long | Equity-common | US | $527K | 44K | 0.51 |
| Xencor, Inc. (Xencor Inc) | Long | Equity-common | US | $1M | 43K | 0.99 |
| Xenon Pharmaceuticals, Inc. (Xenon Pharmaceuticals Inc) | Long | Equity-common | CA | $2M | 53K | 1.96 |
| Zai Lab, Ltd. (Zai Lab Ltd) | Long | Equity-common | KY | $1M | 70K | 1.20 |
| Zentalis Pharmaceuticals, Inc. (Zentalis Pharmaceuticals Inc) | Long | Equity-common | US | $593K | 50K | 0.57 |
Address
ALPS ETF Trust
1290 Broadway, Suite 1000
Denver
Colorado
80203
United States of America
Websites
Directors
Rick A. Pederson
Edmund J. Burke
Jeremy W. Deems
Mary K. Anstine
Transfer Agents
State Street Bank and Trust Company
Pricing Services
Bloomberg Global Markets Services LLC
ICE Data Pricing & Reference Data, LLC
REFINITIV LIMITED
Custodians
State Street Bank and Trust Company
Shareholder Servicing Agents
N/A
Admins
ALPS Fund Services, Inc.
Brokers
MISCHLER FINANCIAL GROUP, INC.